Studies have shown that B‐cell lymphoblastic cell lines (LCLs), produced by EBV transforming B‐lymphocytes in peripheral blood lymphocytes, effectively suppress CD8+ T‐cell responses in MS patients. The gene discussed is CD8A; the disease is myeloid sarcoma.